Dyslipidemia VizARD: Novartis Malaysia Cutting-Edge Solution for Cardiovascular Health in Japan
Novartis Malaysia wins the pharmaceuticals trophy at the recently concluded Malaysia Technology Excellence Awards 2023.
Dyslipidemia is a major risk factor for cardiovascular disease, which is the leading cause of disability and death worldwide. Whilst statins are effective in lowering cholesterol, there is a growing need to take a more comprehensive approach to manage dyslipidemia.
To help address this need, the CONEXTS business specialists’ team at Novartis Corporate Center Kuala Lumpur (NOCC KL) has developed Dyslipidemia VizARD, an advanced real-world data visualisation dashboard to explore and analyse complex datasets through interactive and visually appealing displays. The dashboard leverages the Japan Medical Data Centre health claim database, which includes data on more than half a million dyslipidemia patients in Japan spanning over 15 years to provide a bird’s eye view of the patient profile and disease landscape.
Dyslipidemia VizARD is a comprehensive tool that links a range of patient and clinical characteristics to differential outcomes in various treatments. The dashboard analyses ten main categories of patient/ clinical characteristics, including types of dyslipidemia, patient demographics, clinical history, family history, high-risk groups, treatment pathways, health-services usage, comorbidities, drinking behaviour, and smoking habits. By associating various characteristics together, such as age, risk groups, and comorbidities, the dashboard can help unveil the states and unmet needs of specific patient groups.
The team has deployed Dyslipidemia VizARD exhaustively for strategic planning to support the product life cycle of innovative medicine for dyslipidemia. The dashboard has also been approved for scientific engagement with external healthcare professionals to identify potential clinical research questions and evidence gaps.
Dyslipidemia VizARD is a flexible and user-friendly web-based dashboard that can be updated from time to time when new patient data is available. The dashboard houses an extensive breadth of curated patient information and is equipped with data-driven key metrics, making it a powerful tool for the epidemiological understanding of dyslipidemia.
As a result of these efforts, the team has won the pharmaceuticals accolade at Malaysia Technology Excellence Awards 2023 for Dyslipidemia VizARD.
The awards programme recognises key innovations as well as major industry disruptors and players in the tech industry of Malaysia, and the company stood out for its innovative real-world data analytics dashboard designed to help clinicians and healthcare professionals better understand and manage dyslipidemia patients in Japan.
NOCC KL is one of six strategically located corporate centres established by Novartis globally. It brings together expert capabilities and talent across functionalities and is an innovation hub that drives the business forward. It is home to 500+ associates who work to deliver on the Novartis purpose of reimagining medicine to improve and extend people’s lives.
“With innovative approaches, we are able to use Real-World Data to develop solutions to improve patient outcomes and drive efficiencies in the healthcare system. We can change the practice of medicines by working with healthcare professionals,” said Elsie Chang, Head of Novartis Corporate Center Kuala Lumpur, whilst speaking about this achievement.
This award is a testament to Novartis’ commitment to reimagine medicine. We work to find innovative ways to improve clinical management and patient outcomes of populations and patients in need.
The Malaysia Technology Excellence Awards is presented by Asian Business Review Magazine. To view the full list of winners, click here. If you want to join the 2024 awards programme and be acclaimed for your company's outstanding contributions in pursuit of technological innovation, please contact Danica Avila at [email protected].